β-cell Failure in Type 2 Diabetes: Postulated Mechanisms and Prospects for Prevention and Treatment.
(2014) In Journal of Clinical Endocrinology and Metabolism 99(6). p.1983-1992- Abstract
- Objective: This report examines the foundation of β-cell failure in type 2 diabetes and suggests areas for future research on the underlying mechanisms that may lead to improved prevention and treatment. Participants: A group of experts participated in a conference on October 14-16, 2013 cosponsored by The Endocrine Society and the American Diabetes Association. A writing group prepared this summary and recommendations. Evidence: The writing group based this report on conference presentations, discussion, and debate. Topics covered include genetic predisposition, the foundations of β-cell failure, natural history of β-cell failure, and impact of therapeutic interventions. Conclusions: β-cell failure is central to the development and... (More)
- Objective: This report examines the foundation of β-cell failure in type 2 diabetes and suggests areas for future research on the underlying mechanisms that may lead to improved prevention and treatment. Participants: A group of experts participated in a conference on October 14-16, 2013 cosponsored by The Endocrine Society and the American Diabetes Association. A writing group prepared this summary and recommendations. Evidence: The writing group based this report on conference presentations, discussion, and debate. Topics covered include genetic predisposition, the foundations of β-cell failure, natural history of β-cell failure, and impact of therapeutic interventions. Conclusions: β-cell failure is central to the development and progression of type 2 diabetes. It antedates and predicts diabetes onset and progression, is in part genetically determined, and often can be identified with accuracy even though current tests are cumbersome and not well standardized. Multiple pathways underlie decreased β-cell function and mass, some of which may be shared and may also be a consequence of processes that initially caused dysfunction. Goals for future research include: 1) Impact the natural history of β-cell failure; 2) Identify and characterize genetic loci for type 2 diabetes; 3) Target β-cell signaling, metabolic, and genetic pathways to improve function/mass; 4) Develop alternative sources of β-cells for cell-based therapy; 5) Focus on metabolic environment to provide indirect benefit to β-cells; 6) Improve understanding of the physiology of responses to bypass surgery; 7) Identify circulating factors and neuronal circuits underlying the axis of communication between the brain and β-cells. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/4430637
- author
- Halban, Philippe A ; Polonsky, Kenneth S ; Bowden, Donald W ; Hawkins, Meredith A ; Ling, Charlotte LU ; Mather, Kieren J ; Powers, Alvin C ; Rhodes, Christopher J ; Sussel, Lori and Weir, Gordon C
- organization
- publishing date
- 2014
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Journal of Clinical Endocrinology and Metabolism
- volume
- 99
- issue
- 6
- pages
- 1983 - 1992
- publisher
- Oxford University Press
- external identifiers
-
- wos:000342340500037
- pmid:24712577
- scopus:84902352296
- pmid:24712577
- ISSN
- 1945-7197
- DOI
- 10.1210/jc.2014-1425
- language
- English
- LU publication?
- yes
- id
- 94843db3-af97-4347-9d23-d14553462253 (old id 4430637)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/24712577?dopt=Abstract
- date added to LUP
- 2016-04-01 10:16:03
- date last changed
- 2022-09-10 23:30:39
@article{94843db3-af97-4347-9d23-d14553462253, abstract = {{Objective: This report examines the foundation of β-cell failure in type 2 diabetes and suggests areas for future research on the underlying mechanisms that may lead to improved prevention and treatment. Participants: A group of experts participated in a conference on October 14-16, 2013 cosponsored by The Endocrine Society and the American Diabetes Association. A writing group prepared this summary and recommendations. Evidence: The writing group based this report on conference presentations, discussion, and debate. Topics covered include genetic predisposition, the foundations of β-cell failure, natural history of β-cell failure, and impact of therapeutic interventions. Conclusions: β-cell failure is central to the development and progression of type 2 diabetes. It antedates and predicts diabetes onset and progression, is in part genetically determined, and often can be identified with accuracy even though current tests are cumbersome and not well standardized. Multiple pathways underlie decreased β-cell function and mass, some of which may be shared and may also be a consequence of processes that initially caused dysfunction. Goals for future research include: 1) Impact the natural history of β-cell failure; 2) Identify and characterize genetic loci for type 2 diabetes; 3) Target β-cell signaling, metabolic, and genetic pathways to improve function/mass; 4) Develop alternative sources of β-cells for cell-based therapy; 5) Focus on metabolic environment to provide indirect benefit to β-cells; 6) Improve understanding of the physiology of responses to bypass surgery; 7) Identify circulating factors and neuronal circuits underlying the axis of communication between the brain and β-cells.}}, author = {{Halban, Philippe A and Polonsky, Kenneth S and Bowden, Donald W and Hawkins, Meredith A and Ling, Charlotte and Mather, Kieren J and Powers, Alvin C and Rhodes, Christopher J and Sussel, Lori and Weir, Gordon C}}, issn = {{1945-7197}}, language = {{eng}}, number = {{6}}, pages = {{1983--1992}}, publisher = {{Oxford University Press}}, series = {{Journal of Clinical Endocrinology and Metabolism}}, title = {{β-cell Failure in Type 2 Diabetes: Postulated Mechanisms and Prospects for Prevention and Treatment.}}, url = {{http://dx.doi.org/10.1210/jc.2014-1425}}, doi = {{10.1210/jc.2014-1425}}, volume = {{99}}, year = {{2014}}, }